Bolt Biotherapeutics reports Q4 EPS (47c), consensus (48c)

Reports Q4 revenue $2.09M, consensus $1.71M. “We made substantial progress advancing our two proprietary clinical-stage development programs in 2023,” said Randall Schatzman, CEO. “We have now administered BDC-1001, which we have renamed trastuzumab imbotolimod, to patients in all five of the Phase 2 cohorts. BDC-3042 also continues to advance, and has now entered the fourth dose escalation cohort without a dose-limiting toxicity. Both clinical programs are on track and we look forward to providing updates later this year.”